{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073363","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.673919+00:00","generated_at":"2026-05-15T23:37:37.738758+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"Indivior Q4 earnings beat; SUBLOCADE rev $252M (+30%); new $400M buyback; FY26 guidance reaffirmed","bullets":["Q4 total net revenue $358M (+20% YoY); SUBLOCADE net revenue $252M (+30%); GAAP diluted EPS $0.79 vs $0.17","Non-GAAP Q4 net income $107M ($0.82 diluted EPS); Adjusted EBITDA $142M (+91% YoY)","FY 2025: revenue $1,239M (+4%), SUBLOCADE $856M (+13%); GAAP net income $210M ($1.64 EPS); adj. EBITDA $428M (+20%)","Board authorized new $400M share repurchase program (up to 18 months) for opportunistic deployment","FY 2026 guidance: SUBLOCADE $905M-$945M, adj. EBITDA $535M-$575M, non-GAAP opex $430M-$450M"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073363","json":"https://secwatch.observer/filing/0001193125-26-073363.json","markdown":"https://secwatch.observer/filing/0001193125-26-073363.md","text":"https://secwatch.observer/filing/0001193125-26-073363.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526073363/0001193125-26-073363-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526073363/d713689d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:37:37.738758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}